
    
      This is a Phase I, first time in human, randomized, double-blind, placebo-controlled, and
      dose escalation study in healthy volunteers.

      The study will comprise of:

        1. A Screening Period of up to 30 days (Day -30 through Day -1);

        2. A Treatment Period during which participants will be resident at the Observation Unit
           from Day -1, 1 day before Investigational Medicinal Product (IMP) administration (on Day
           1) until at least 24 hours after IMP administration, will be discharged on Day 2 after
           all safety and/or pharmacokinetic (PK) evaluations have been completed, and

        3. A Follow up Period lasting 180 days after the IMP dose. The study will be conducted at a
           single study center in Cincinnati.
    
  